戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 risk of reoperation for bleeding or need for blood product transfusion.
2 tients (69%), and 28 patients (67%) required blood product transfusion.
3 nt has reduced intraoperative blood loss and blood product transfusions.
4 iated with major blood loss and the need for blood product transfusions.
5 ed growth factor support, and three required blood product transfusions.
6 , continuous veno-venous hemofiltration, and blood product transfusions.
7 2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001),
8 ump CABG, significantly reduced the rates of blood-product transfusion (50.7% vs. 63.3%; relative ris
9 4%; P=0.96) or requirement for postoperative blood product transfusion (adjusted OR, 1.17; 95% CI, 0.
10 irus infection that presumably resulted from blood product transfusions administered before the intro
11 s is likely related to the administration of blood product transfusion after the onset of fulminant h
12 ndrome continues to be supportive care, with blood product transfusion and antibiotics for infectious
13 nal shock, maternal requirement of allogenic blood product transfusion and lower gestational age were
14  to intervention, total procedural duration, blood product transfusion and salvages a small subset of
15                                    Bleeding, blood product transfusions, and thrombosis were not diff
16  and related physician orders, demographics, blood products transfusion, and outcomes were collected
17 ntly, Jehovah's Witness patients, who refuse blood product transfusion, are usually excluded from liv
18                                    Sedation, blood product transfusions as indicated, antibiotics, an
19 ology may have false-positive results due to blood product transfusion-associated passive immunity.
20  seropositive, and who received more than 20 blood product transfusions before BMT.
21 ostatic reoperation and the requirements for blood product transfusions during and after off-pump cor
22 et count), and its use may avoid unnecessary blood product transfusion in patients with cirrhosis and
23 Timely LDLT can be done successfully without blood product transfusion in selected patients.
24 eeding are among the most common reasons for blood product transfusion in surgical practices.
25                           Red blood cell and blood product transfusion in the fetus, neonate, and pre
26                                 Receipt of a blood product transfusion in the prehospital setting com
27                                  Prehospital blood product transfusion in trauma care remains controv
28 rs such as total parenteral nutrition (TPN), blood product transfusions, invasive procedures, central
29 tality (odds ratio, 0.40; P=0.017), need for blood product transfusion (odds ratio, 0.74; P=0.009), m
30  to treat, 22.6), but had no effect on other blood product transfusions or major complications.
31                                  Restrictive blood product transfusion practices following congenital
32  military combat causalities in Afghanistan, blood product transfusion prehospital or within minutes
33 n the incidence of hemostatic reexploration, blood product transfusion rates, morbidity, and mortalit
34       Early postoperative chest-tube output, blood-product transfusion requirements, and levels of se
35 ocol, all subjects in the SOC group received blood product transfusions versus 5 in the TEG group (10
36   No significant clinical bleeding events or blood product transfusions were observed in this trial.
37 Pugh B: 26; C: 58) without overt bleeding or blood-product transfusion were prospectively evaluated w
38 m amplitude were also less likely to receive blood product transfusions within 24 hours of testing co